These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37182269)

  • 1. Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma.
    Jikuya R; Johnson TA; Maejima K; An J; Ju YS; Lee H; Ha K; Song W; Kim Y; Okawa Y; Sasagawa S; Kanazashi Y; Fujita M; Imoto S; Mitome T; Ohtake S; Noguchi G; Kawaura S; Iribe Y; Aomori K; Tatenuma T; Komeya M; Ito H; Ito Y; Muraoka K; Furuya M; Kato I; Fujii S; Hamanoue H; Tamura T; Baba M; Suda T; Kodama T; Makiyama K; Yao M; Shuch BM; Ricketts CJ; Schmidt LS; Linehan WM; Nakagawa H; Hasumi H
    EBioMedicine; 2023 Jun; 92():104596. PubMed ID: 37182269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report.
    Li J; Liu F; Liu X; Hu Y; Liu Z; Shen Y; Wan J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2319-2325. PubMed ID: 36258004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC; Gijezen LM; Jonker MA; van Doorn MB; Oldenburg RA; van Spaendonck-Zwarts KY; Leter EM; van Os TA; van Grieken NC; Jaspars EH; de Jong MM; Bongers EM; Johannesma PC; Postmus PE; van Moorselaar RJ; van Waesberghe JH; Starink TM; van Steensel MA; Gille JJ; Menko FH
    Br J Cancer; 2011 Dec; 105(12):1912-9. PubMed ID: 22146830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Iribe Y; Kuroda N; Nagashima Y; Yao M; Tanaka R; Gotoda H; Kawakami F; Imamura Y; Nakamura Y; Ando M; Araki A; Matsushima J; Nakatani Y; Furuya M
    Pathol Int; 2015 Mar; 65(3):126-32. PubMed ID: 25597876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birt-Hogg-Dubé syndrome in an overall view: Focus on the clinicopathological prospects in renal tumors.
    Wu J; Lu J; Wu CL; Lu M
    Semin Diagn Pathol; 2024 May; 41(3):119-124. PubMed ID: 38242750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Uniparental Disomy and Copy Number Variations in Renal Cell Carcinomas Associated with Birt-Hogg-Dubé Syndrome.
    Iribe Y; Yao M; Tanaka R; Kuroda N; Nagashima Y; Nakatani Y; Furuya M
    Am J Pathol; 2016 Feb; 186(2):337-46. PubMed ID: 26776076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome.
    Schmidt LS; Linehan WM
    Nat Rev Urol; 2015 Oct; 12(10):558-69. PubMed ID: 26334087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal hybrid oncocytic/chromophobe tumors - a review.
    Hes O; Petersson F; Kuroda N; Hora M; Michal M
    Histol Histopathol; 2013 Oct; 28(10):1257-64. PubMed ID: 23740406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study.
    Benusiglio PR; Giraud S; Deveaux S; Méjean A; Correas JM; Joly D; Timsit MO; Ferlicot S; Verkarre V; Abadie C; Chauveau D; Leroux D; Avril MF; Cordier JF; Richard S;
    Orphanet J Rare Dis; 2014 Oct; 9():163. PubMed ID: 25519458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
    Murakami T; Sano F; Huang Y; Komiya A; Baba M; Osada Y; Nagashima Y; Kondo K; Nakaigawa N; Miura T; Kubota Y; Yao M; Kishida T
    J Pathol; 2007 Apr; 211(5):524-531. PubMed ID: 17323425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.
    Klomp JA; Petillo D; Niemi NM; Dykema KJ; Chen J; Yang XJ; Sääf A; Zickert P; Aly M; Bergerheim U; Nordenskjöld M; Gad S; Giraud S; Denoux Y; Yonneau L; Méjean A; Vasiliu V; Richard S; MacKeigan JP; Teh BT; Furge KA
    BMC Med Genomics; 2010 Dec; 3():59. PubMed ID: 21162720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birt-Hogg-Dubé syndrome-associated renal cell carcinoma: Histopathological features and diagnostic conundrum.
    Furuya M; Hasumi H; Yao M; Nagashima Y
    Cancer Sci; 2020 Jan; 111(1):15-22. PubMed ID: 31777168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
    Nahorski MS; Lim DH; Martin L; Gille JJ; McKay K; Rehal PK; Ploeger HM; van Steensel M; Tomlinson IP; Latif F; Menko FH; Maher ER
    J Med Genet; 2010 Jun; 47(6):385-90. PubMed ID: 20522427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.